Re-join your expert speakers in a closing panel discussion as they explore the best approaches to characterize, predict and mitigate ADC’s largest barrier to widen therapeutic index. Bring your top questions as the speakers discuss best methods to predict ADC clinical safety profiles, optimize patient selection, and mitigate adverse events.

Discussion Highlights Include:

• Understanding transferable learnings and new considerations to assess the safety profile of non-cytotoxic and novel format ADCs
• Breaking down how best to deploy in vivo and in vitro models to improve prediction of ADC clinical
• safety profiles
• Tackling opportunities and strategies to identify high risk patients and mitigate clinical ADC toxicities
• What are the toxicity-led barriers to overcome for ADCs progression to earlier-line patient therapies